FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1551289085> ?p ?o ?g. }

• W1551289085 endingPage "313" @default.
• W1551289085 startingPage "313" @default.
• W1551289085 abstract "Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data Gary Bloomgren, Bjørn Sperling, Kimberly Cushing, Madé WentenBiogen Idec Inc., Weston, MA, USABackground: Intramuscular interferon beta-1a (IFNβ-1a), a multiple sclerosis (MS) therapy that has been commercially available for over a decade, provides a unique opportunity to retrospectively assess postmarketing data for evidence of malignancy risk, compared with relatively limited data available for more recently approved therapies. Postmarketing and claims data were analyzed to determine the risk of malignancy in MS patients treated with intramuscular IFNβ-1a.Materials and methods: The cumulative reporting rates of suspected adverse drug reactions coded to malignancy in the intramuscular IFNβ-1a global safety database were compared with malignancy incidence rates in the World Health Organization GLOBOCAN database. In addition, using data from a large US claims database, the cumulative prevalence of malignancy in MS patients treated with intramuscular IFNβ-1a was compared with non-MS population controls, MS patients without intramuscular IFNß-1a use, and untreated MS patients. Mean follow-up was approximately 3 years for all groups, ie, 3.1 years for the intramuscular IFNβ-1a group (range 0.02–6.0 years), 2.6 years for non-MS population controls (range 0–6.0 years), 2.6 years for the intramuscular IFNβ-1a nonuse group (range 0.01–6.0 years), and 2.4 years for the untreated MS group (range 0.01–6.0 years).Results: An estimated 402,250 patients received intramuscular IFNβ-1a during the postmarketing period. Cumulative reporting rates of malignancy in this population were consistent with GLOBOCAN incidence rates observed within the general population. The claims database included 12,894 MS patients who received intramuscular IFNβ-1a. No significant difference in malignancy prevalence was observed in intramuscular IFNβ-1a users compared with other groups.Conclusion: Results from this evaluation provide no evidence of an increased risk of malignancy with intramuscular IFNβ-1a use.Keywords: multiple sclerosis, malignancy, safety, intramuscular interferon beta-1a, postmarketing surveillance, claims" @default.
• W1551289085 created "2016-06-24" @default.
• W1551289085 creator A5018875655 @default.
• W1551289085 creator A5064660082 @default.
• W1551289085 creator A5073093450 @default.
• W1551289085 creator A5085931384 @default.
• W1551289085 date "2012-06-01" @default.
• W1551289085 modified "2023-09-24" @default.
• W1551289085 title "Assessment of malignancy risk in patients with multiple sclerosis treated with intramuscular interferon beta-1a: retrospective evaluation using a health insurance claims database and postmarketing surveillance data" @default.
• W1551289085 cites W1981989535 @default.
• W1551289085 cites W1990163353 @default.
• W1551289085 cites W1992839581 @default.
• W1551289085 cites W2003235760 @default.
• W1551289085 cites W2013691673 @default.
• W1551289085 cites W2029151440 @default.
• W1551289085 cites W2030063800 @default.
• W1551289085 cites W2035559041 @default.
• W1551289085 cites W2036645664 @default.
• W1551289085 cites W2047876790 @default.
• W1551289085 cites W2069627378 @default.
• W1551289085 cites W2083339580 @default.
• W1551289085 cites W2112291250 @default.
• W1551289085 cites W2117987455 @default.
• W1551289085 cites W2120791515 @default.
• W1551289085 cites W2139367012 @default.
• W1551289085 cites W2168968747 @default.
• W1551289085 cites W2170672646 @default.
• W1551289085 cites W2313649737 @default.
• W1551289085 doi "https://doi.org/10.2147/tcrm.s31347" @default.
• W1551289085 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3387830" @default.
• W1551289085 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22767995" @default.
• W1551289085 hasPublicationYear "2012" @default.
• W1551289085 type Work @default.
• W1551289085 sameAs 1551289085 @default.
• W1551289085 citedByCount "6" @default.
• W1551289085 countsByYear W15512890852013 @default.
• W1551289085 countsByYear W15512890852014 @default.
• W1551289085 countsByYear W15512890852015 @default.
• W1551289085 countsByYear W15512890852018 @default.
• W1551289085 countsByYear W15512890852019 @default.
• W1551289085 countsByYear W15512890852023 @default.
• W1551289085 crossrefType "journal-article" @default.
• W1551289085 hasAuthorship W1551289085A5018875655 @default.
• W1551289085 hasAuthorship W1551289085A5064660082 @default.
• W1551289085 hasAuthorship W1551289085A5073093450 @default.
• W1551289085 hasAuthorship W1551289085A5085931384 @default.
• W1551289085 hasBestOaLocation W15512890851 @default.
• W1551289085 hasConcept C120665830 @default.
• W1551289085 hasConcept C121332964 @default.
• W1551289085 hasConcept C126322002 @default.
• W1551289085 hasConcept C167135981 @default.
• W1551289085 hasConcept C187212893 @default.
• W1551289085 hasConcept C197636746 @default.
• W1551289085 hasConcept C197934379 @default.
• W1551289085 hasConcept C203014093 @default.
• W1551289085 hasConcept C2776291583 @default.
• W1551289085 hasConcept C2779399171 @default.
• W1551289085 hasConcept C2780640218 @default.
• W1551289085 hasConcept C2908647359 @default.
• W1551289085 hasConcept C41008148 @default.
• W1551289085 hasConcept C61511704 @default.
• W1551289085 hasConcept C71924100 @default.
• W1551289085 hasConcept C77088390 @default.
• W1551289085 hasConcept C99454951 @default.
• W1551289085 hasConceptScore W1551289085C120665830 @default.
• W1551289085 hasConceptScore W1551289085C121332964 @default.
• W1551289085 hasConceptScore W1551289085C126322002 @default.
• W1551289085 hasConceptScore W1551289085C167135981 @default.
• W1551289085 hasConceptScore W1551289085C187212893 @default.
• W1551289085 hasConceptScore W1551289085C197636746 @default.
• W1551289085 hasConceptScore W1551289085C197934379 @default.
• W1551289085 hasConceptScore W1551289085C203014093 @default.
• W1551289085 hasConceptScore W1551289085C2776291583 @default.
• W1551289085 hasConceptScore W1551289085C2779399171 @default.
• W1551289085 hasConceptScore W1551289085C2780640218 @default.
• W1551289085 hasConceptScore W1551289085C2908647359 @default.
• W1551289085 hasConceptScore W1551289085C41008148 @default.
• W1551289085 hasConceptScore W1551289085C61511704 @default.
• W1551289085 hasConceptScore W1551289085C71924100 @default.
• W1551289085 hasConceptScore W1551289085C77088390 @default.
• W1551289085 hasConceptScore W1551289085C99454951 @default.
• W1551289085 hasLocation W15512890851 @default.
• W1551289085 hasLocation W15512890852 @default.
• W1551289085 hasLocation W15512890853 @default.
• W1551289085 hasLocation W15512890854 @default.
• W1551289085 hasOpenAccess W1551289085 @default.
• W1551289085 hasPrimaryLocation W15512890851 @default.
• W1551289085 hasRelatedWork W1551289085 @default.
• W1551289085 hasRelatedWork W2066797670 @default.
• W1551289085 hasRelatedWork W2095430619 @default.
• W1551289085 hasRelatedWork W2140757319 @default.
• W1551289085 hasRelatedWork W2275480158 @default.
• W1551289085 hasRelatedWork W2388388774 @default.
• W1551289085 hasRelatedWork W2617222556 @default.
• W1551289085 hasRelatedWork W2758813331 @default.
• W1551289085 hasRelatedWork W2914752722 @default.
• W1551289085 hasRelatedWork W3154734119 @default.
• W1551289085 isParatext "false" @default.

• next